期刊
JOURNAL OF CLINICAL ONCOLOGY
卷 35, 期 9, 页码 968-974出版社
AMER SOC CLINICAL ONCOLOGY
DOI: 10.1200/JCO.2016.71.0806
关键词
-
类别
资金
- National Institutes of Health [R01 HL082945, R24 DK099808]
- US Department of Defense
- Edward P. Evans Foundation
- Leukemia & Lymphoma Society
- STARR Cancer Consortium
Myelodysplastic syndrome (MDS) is clonal disorder characterized by ineffective hematopoiesis and a tendency to evolve into acute myeloid leukemia (AML). Genetic studies have enabled the identification of a set of recurrently mutated genes central to the pathogenesis of MDS, which can be organized into a limited number of cellular processes, including RNA splicing, epigenetic and traditional transcriptional regulation, and signal transduction. The sequential accumulation of mutations drives disease evolution from asymptomatic clonal hematopoiesis to frank MDS, and, ultimately, to secondary AML. This detailed understanding of the molecular landscape of MDS, coupled with the emergence of cost-and time-effective methodologies for DNA sequencing has led to the introduction of genetic studies into the clinical realm. Here, we review recent advances in our genetic understanding of MDS, with a particular focus on the emerging role for mutational data in clinical management as a potential tool to assist in diagnosis, risk stratification, and therapeutic decision-making. (C) 2017 by American Society of Clinical Oncology
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据